Jill Feldman: In what universe is 4 – 6 loose stools a day considered tolerable???
Jill Feldman recently shared a post by Stacey Tinianov, Vice President of Patient Advocacy and Engagement at on X, adding the following:
“Seriously, & pain, bloating, urgency, incontinence, aren’t included in grade
Safety is an endpoint for clinical trials, NOT tolerability or QOL – you can’t quantify impact!
Need to characterize Grade 1 & 2 AE’s in the context of people’s lives.
Grade 2 diarrhea NOT tolerable!”
Quoting Stacey Tinianov:
“‘In what universe is 4 – 6 loose stools a day considered tolerable???’ Jill Feldman in MASCC webinar on GI side effects in cancer care.
This lived experience is the real measure.”
Source: Jill Feldman/X and Stacey Tinianov/X
Jill Feldman is a lung cancer patient and advocate. She is the Co-Founder EGFR Resisters, an advocacy group of EGFR positive lung cancer patients who are resistant to targeted treatment. She is the Past President of the LUNGevity Foundation, Deputy Chair of IASLC’s patient advisory board and a member of The Chicago Institute of Translational Medicine’s patient advisory board. Jill is committed to understanding and promoting patient-centered research as a member of the programmatic panel for the Department of Defense Lung Cancer Research Program, as a planning committee member on IASLC’s North America Conference on Lung cancer and as a member of the the ECOG-ACRIN Research Group’s patient advocate committee and thoracic committee.